BCL2L1 and neoplasm: During tumor regression, there is a reduction in proliferative and antiapoptotic molecules such as cyclin D1 and Bcl-XL, respectively; and an increase in BAX release, leading to the activation of the intrinsic apoptotic mechanism of caspase 9.